Neratinib for HER2-positive breast cancer with an overlooked option
This article reviewed the pharmacological profiles, efficacy, safety, tolerability, and current clinical trials pertaining to neratinib, with a particular focus on the use of neratinib in patients with metastatic breast cancer (MBC) involving the CNS. We further discussed the use of neratinib for HER2-negative and HER2-mutant breast cancers, and mechanisms of resistance to neratinib. The current evidence suggests that neratinib has promising efficacy in patients with BC which is at least non-inferior compared to previous therapeutic regimens. The most common AE was diarrhea, and the incidence, severity and duration of neratinib-related grade 3 diarrhea can be reduced with loperamide. Of note, neratinib has the potential to effectively control and prevent brain metastasis in patients with advanced BC, providing a therapeutic strategy for HER2-positive BC.PMID:37803271 | DOI:10.1186/s10020-023-00736-0
Source: Molecular Medicine - Category: Molecular Biology Authors: Liting Guo Weiwei Shao Chenfei Zhou Hui Yang Liu Yang Qu Cai Junqing Wang Yan Shi Lei Huang Jun Zhang Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Herceptin | Imodium | Loperamide | Molecular Biology | Neoadjuvant Therapy | Neurology | Xeloda